Several studies have been made with the intention of developing alternatives to contribute to a best survival of the melanoma patient. The anti-melanoma vaccines were developed to induce the patient's specific immunity against the tumor through the immunization with tumor cells or with their antigenic components. The vaccines of first generation include the prepared ones with lysed of whole cells, like Melacine®; autologous melanoma cells treated with hapten, like M-Vax®; and the allogenic irradiated cells, like CancerVax®. Later came the vaccines of second generation: vaccine of tumor cells modified with cytocine factors, vaccines with dendritic cells and, vaccines with bacterial and viral vectors modified genetically. We structured an unit fully dedicated to the research and development of these new therapeutic options and at the moment we have two Phase 1 clinical protocol approved by Ethics Committee, open, recruiting patients. The first one is a polipeptide vaccine (Melanin-A/Mart 1, Tyrosinase, gp100) associated to GM-CSF intra-linfonodal in melanoma patients with high recurrence risk. It is a vaccine designed to try to reduce the recurrence index of disease. The second one is a dendritic cell based vaccine with autologous dendritic cells pulsed with lysed and apoptotic tumor bodies.